<International Circulation>: What is the recent development in other anticoagulant agents such as the anti-Xa compound for stroke prevention?
Prof. Diener: There are several compounds that are now in phase II and Phase III but the trials have not been terminated so we do not yet know how they compare to dabigatran.
[1] [2] [3] [4] [5] 6 [上一页]